文献速递瓣膜外科

70岁以下患者主动脉瓣置换术后中期结局:INSPIRIS RESILIA与PERIMOUNT MAGNA EASE生物瓣比较

Mid-Term Outcomes After Aortic Valve Replacement in Patients Under 70: A Comparative Study of INSPIRIS RESILIA Versus PERIMOUNT MAGNA EASE Bioprostheses.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2025-01-01

本研究为单中心回顾性研究,比较70岁以下患者使用INSPIRIS RESILIA与PERIMOUNT MAGNA EASE生物瓣行主动脉瓣置换术的中期临床与超声心动图结局。两种瓣膜中期安全性和性能相似。

要点

  • 匹配后两组3年全因死亡率分别为0%与1.9%,差异无统计学报告。
  • 1年与3年平均跨瓣压差两组相似(1年11.3 vs 11.2 mmHg,3年均为12.9 mmHg)。

核心结论

  • 在70岁以下主动脉瓣置换患者中,INSPIRIS RESILIA与PERIMOUNT MAGNA EASE生物瓣的中期安全性和性能相似。

研究设计与样本

  • 单中心回顾性研究,纳入2018年1月至2023年5月在Reims大学医院行外科主动脉瓣置换术的患者。
  • 共纳入300例,INSPIRIS组52例,PERIMOUNT组248例,匹配后每组各52例进行比较。
  • 主要结局为术后1年全因死亡率,次要结局包括血流动力学参数、左心室射血分数及主要术后并发症。

主要发现

  • 匹配后3年全因死亡率INSPIRIS组为0%,PERIMOUNT组为1.9%。
  • 平均跨瓣压差1年时分别为11.3 mmHg与11.2 mmHg,3年时两组均为12.9 mmHg。
  • INSPIRIS组发生2例因感染性心内膜炎再次手术,未观察到需手术的结构性瓣膜退化。
  • 术后主动脉瓣反流均为轻微或无。

临床怎么用

  • 在70岁以下患者中,两种生物瓣均可提供相似的中期血流动力学表现和安全性。
  • INSPIRIS组输血率较低,围术期血液管理可能获益。
  • 需关注INSPIRIS组感染性心内膜炎相关再手术风险。

局限性

  • 本研究为单中心回顾性研究,样本量有限,匹配后每组仅52例。
  • 随访时间限于中期,缺乏长期耐久性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: INSPIRIS RESILIA, launched in 2017, is a bioprosthetic aortic valve developed to improve durability and facilitate future valve-in-valve procedures. Despite its advanced design, many surgeons continue to use the PERIMOUNT MAGNA EASE valve, which has long-standing clinical validation. This study aimed to compare mid-term clinical and echocardiographic outcomes in patients under 70 undergoing aortic valve replacement with either prosthesis. METHODS: We conducted a retrospective study of patients who underwent surgical aortic valve replacement between January 2018 and May 2023 at the University Hospital of Reims. The primary outcome was all-cause mortality at 1 year following surgical aortic valve replacement. Secondary outcomes included haemodynamic parameters, left ventricular ejection fraction, and major postoperative complications such as reintervention, stroke, pacemaker implantation, mediastinitis, transfusion, and new-onset atrial fibrillation. RESULTS: A total of 300 patients were included: 52 received the INSPIRIS RESILIA valve and 248 received the PERIMOUNT MAGNA EASE valve. After matching, 52 patients from each group were compared. All-cause mortality at 3 years was 0% in the INSPIRIS group and 1.9% in the PERIMOUNT group. Mean transvalvular gradients were similar at 1 year (11.3 vs 11.2 mmHg) and 3 years (12.9 mmHg for both). Two cases of endocarditis-related reoperation occurred in the INSPIRIS group. No structural valve degeneration requiring surgery was observed. Postoperative aortic regurgitation was trivial or absent. Transfusion rates were lower in the INSPIRIS group (46.1% vs 69.2%, P = .017). CONCLUSIONS: INSPIRIS RESILIA and MAGNA EASE valves offer similar mid-term safety and performance in patients under 70 years of age.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Saiydoun G, Nassar E, Saadé S, et al. Mid-Term Outcomes After Aortic Valve Replacement in Patients Under 70: A Comparative Study of INSPIRIS RESILIA Versus PERIMOUNT MAGNA EASE Bioprostheses. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40712048. doi:10.1093/icvts/ivaf169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。